Palisade Bio to Present Phase 1 Data for Ulcerative Colitis Drug at DDW 2026
Event summary
- Palisade Bio's abstract on PALI-2108 selected for poster presentation at DDW 2026 on May 5, 2026.
- Poster titled 'Gut-Targeted PDE4 Inhibition with PALI-2108 Demonstrates Rapid Clinical, Histologic and Biomarker Improvement in Ulcerative Colitis'.
- Company advancing toward Phase 2 clinical study in ulcerative colitis.
- PALI-2108 is a once-daily oral PDE4 inhibitor prodrug designed for gut-targeted delivery.
The big picture
Palisade Bio's presentation at DDW 2026 highlights the growing focus on targeted therapies for inflammatory bowel disease. The company's prodrug platform aims to improve upon existing PDE4 inhibitors by enhancing gut-specific delivery, a strategy that could differentiate it in a crowded market. The upcoming Phase 2 trial will be critical in validating this approach and attracting potential partners or investors.
What we're watching
- Clinical Efficacy
- How Phase 1 data will position PALI-2108 against existing ulcerative colitis treatments.
- Regulatory Pathway
- The pace at which Palisade Bio advances toward Phase 2 trials and potential FDA interactions.
- Market Differentiation
- Whether gut-targeted delivery can provide a meaningful advantage in the competitive IBD space.
Related topics